NSE filing, NSE: VILINBIO. Summary written from the filing by ALFA Finder's alert engine.
Vilin Bio Med Ltd: key numbers
- Share price
- ₹50.85
- Market cap
- ₹77.55 Cr
- Revenue (annual)
- ₹42.26 Cr
- Net profit (annual)
- ₹1.93 Cr
- P/E (TTM)
- 40.2×Sector 46.5×
- Promoter holding
- 56.65%+0.00% QoQ
- FII holding
- 0.13%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Vilin Bio Med Ltd
All →Vilin Bio Med Acquisition
Vilin Bio Med held NCLT-convened meetings to approve a scheme of amalgamation with Chemgenix Laboratories. Voting results remain pending in the Scrutinizer's report.
Vilin Bio Med Merger & Restructuring
Vilin Bio Med Limited announced an NCLT-convened meeting on October 15, 2026, to vote on a Scheme of Arrangement with Chemgenix Laboratories Private Limited.
Vilin Bio Med Board Meeting Date
Vilin Bio Med Limited scheduled a board meeting for September 18, 2026, to consider an amalgamation proposal. Trading window remains closed until September 20, 2026.
Vilin Bio Med Acquisition
Vilin Bio Med disclosed NCLT Hyderabad allowed its amalgamation with Chemgenix Laboratories Pvt Ltd. The order directs convening shareholder and creditor meetings for both companies.
Vilin Bio Med Annual General Meeting
Vilin Bio Med Limited conducted its 20th Annual General Meeting on September 2, 2026, to discuss financial statements, director appointments, and related party transactions.
Vilin Bio Med Merger & Restructuring
Vilin Bio Med received a 'No Objection' observation letter from the NSE regarding its merger with Chemgenix Laboratories. The scheme remains subject to further statutory and creditor approvals.
Other other announcement announcements
All →eMudhra Other Announcement
eMudhra Ltd disclosed that SES ESG revised its ESG score from 68.0 to 64.9 in its ESG Report 2026. The company states it did not engage SES ESG, and the revision relates to its certificate business.
Aarti Pharmalabs Other Announcement
Aarti Pharmalabs has intimated under Regulation 46 that it revamped its website at the existing URL to improve design and accessibility. The notice has no financial or business substance.
Sagarsoft (India) Other Announcement
Sagarsoft (India) filed its Regulation 32 fund utilisation statement for its 2021 preferential issue. No deviation was reported and the full Rs.5.08 Crore was used.
Sadhana Nitro Chem Other Announcement
Sadhana Nitro Chem reported no deviation in use of its preferential issue proceeds for the quarter ended September 2026. The Audit Committee reviewed the statement.
Shriram Asset Management Company Other Announcement
Shriram AMC filed ICRA's quarterly monitoring agency report on preferential issue proceeds. Utilisation is in line with the offer objects, with no deviation reported.
Jhandewalas Foods Other Announcement
Jhandewalas Foods filed its quarterly shareholding pattern for the period ended September 30, 2026. The filing records holdings by category and contains no transaction or money event.